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Mutational signatures in colon cancer
Priyatama Pandey1, Zhi Yang1, Darryl Shibata2, Paul Marjoram1 and Kimberly D. Siegmund1* 
Abstract 
Objective: Recently, many tumor sequencing studies have inferred and reported on mutational signatures, short 
nucleotide patterns at which particular somatic base substitutions appear more often. A number of signatures reflect 
biological processes in the patient and factors associated with cancer risk. Our goal is to infer mutational signatures 
appearing in colon cancer, a cancer for which environmental risk factors vary by cancer subtype, and compare the 
signatures to those in adult stem cells from normal colon. We also compare the mutational signatures to others in the 
literature.
Results: We apply a probabilistic mutation signature model to somatic mutations previously reported for six adult 
normal colon stem cells and 431 colon adenocarcinomas. We infer six mutational signatures in colon cancer, four 
being specific to tumors with hypermutation. Just two signatures explained the majority of mutations in the small 
number of normal aging colon samples. All six signatures are independently identified in a series of 295 Chinese 
colorectal cancers.
Keywords: Somatic mutations, Mutational process, Topic model, Latent Dirichlet allocation model
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Introduction
The first large study of somatic mutations in cancer iden-
tified 20 mutational signatures in 7042 primary tumors 
from 30 different classes [1]. They defined mutational 
signatures by patterns of three consecutive nucleotides, 
including one base 3 ′  and one 5 ′  of the nucleotide sub-
stitution, and represented by a linear combination of the 
96-possible three-base patterns. The mutational signa-
tures were annotated and published in the Catalogue of 
Somatic Mutations in Cancer (COSMIC) database [2]. 
Four signatures were identified in 557 colorectal cancers 
[1], three signatures with probable associations attrib-
uted to one of the mechanisms of aging, DNA mismatch 
repair, or Pol ǫ mutation and the fourth of unknown 
origin.
A simple probabilistic model for mutational signa-
tures, proposed shortly thereafter, assumed independ-
ent contributions (i.e., multiplicative probabilities) of the 
neighboring bases composing the nucleotide pattern [3]. 
This resulted in a more parsimonious model with fewer 
parameters and the ability to detect longer five-base sig-
nature patterns. A reanalysis of the same colon cancer 
data using this new probabilistic model also reported 
four mutational signatures, but their make-up was dif-
ferent. The previous Pol ǫ signature was split into two 
signatures, one favoring C > T mutations at TpCpG 
and the second favoring C > A at TpTpCpT, a signature 
four bases in length. The remaining two signatures were 
attributed to aging, and unknown origin. Interestingly, 
the DNA mismatch repair signature was not reported.
Today, the number of single-base substitution sig-
natures in the COSMIC database has increased to 49; 
seven of these signatures relate to DNA mismatch-repair 
(MMR) deficiency. Recent studies characterizing cancers 
with hypermutation [4] and cancers along the gastroin-
testinal tract [5, 6] reported multiple MMR signatures. 
A recent reanalysis of data from the Cancer Genome 
Atlas by Liu et al. identified six signatures in colon can-
cer [6], four of which are identified as occurring primar-
ily in cancers with high mutational burden. We sought to 
understand the connection between these six mutational 
signatures and those found using the probability muta-
tional signature model.
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In addition to studying the variation in mutational sig-
natures appearing in different subtypes of colon cancers, 
we investigated whether the mutational signatures dif-
fered across different time periods. We classified somatic 
mutations by their time of occurrence, occurring in the 
original tumor cell (‘trunk’ mutation) or appearing de 
novo during tumor growth (‘branch’ mutation), and com-
pared their signatures to those found in adult stem cells 
from normal colon. We exploit publicly available data 
from a study of adult stem cells (ASCs) in normal colon 
[7], the Cancer Genome Atlas (TCGA), and the Interna-
tional Cancer Genomics Consortium (ICGC). Our analy-
sis identifies six mutational signatures using ASCs and 
TCGA colon cancers that are validated in the ICGC Chi-
nese colorectal cancers.
Main text
Data
Human adult stem cells (ASCs) from normal colon
Whole genome sequencing of 21 samples from 6 human 
ASCs from normal colon was performed and published 
in [7]. Processed somatic mutation data were down-
loaded from [8].
TCGA colon adenocarcinoma (COAD‑US)
We downloaded somatic mutation data from 435 colon 
adenocarcinoma from the Genomic Data Commons Data 
Portal [9]. The tumor characteristic microsatellite insta-
bility (high, low, stable) was downloaded as part of the 
clinical data. A total of 431 samples with somatic muta-
tion data had information on microsatellite instability. 
We obtained the variable on Pol ǫ mutation from the sup-
plementary data in [10]. We note that our downloading 
and filtering of the TCGA data resulted in notable differ-
ences from the previously analyzed data made available 
in [1, 3].
We classified mutations by their time of occurrence 
(trunk/branch) by applying the criteria of Williams et al. 
[11], using information on tumor purity and allele fre-
quency. We restricted our data set to the COAD-US sam-
ples in [11] with purity ≥ 70% (n = 99), and classified the 
mutations with frequency ≥ 0.25 as trunk and the rest as 
branch. After mutation classification, six samples with 
fewer than 10 mutations along with their tumor-matched 
sample were omitted from further analysis.
Colorectal adenocarcinoma in China (COCA‑CN)
The somatic mutation data in Chinese colorectal adeno-
carcinoma were downloaded from the ICGC Data Portal 
[12]. This data set contains 2,941,990 mutations in 295 
Chinese colorectal samples.
See Additional file 1 for details on mutation filtering.
Statistical methods
We applied the probabilistic mutation signature model 
[3] to infer mutation signatures and their exposure fre-
quencies in normal colon ASCs and COAD-US tumor 
samples. We restricted all samples to mutations on 
chromosomes 1–22 and fit the model using the pmsig-
nature package in R [3]. We specify the model for a 
five-base context and include the direction of the tran-
scription strand (positive/negative). The four nucleo-
tides flanking the substitution, two upstream and two 
downstream, are extracted from the reference genome. 
As the ASCs from normal colon and COAD-US sam-
ples were sequenced at different times and mapped 
to different reference genomes, flanking bases are 
extracted using the same reference to which the corre-
sponding sample was mapped, (hg19 for ASC samples 
and hg38 for COAD-US). We selected the optimum 
number of latent mutational signatures by minimizing 
the Bayesian Information Criterion (BIC) and the boot-
strap standard errors for the model parameters [3].
The Shiny app iMutSig [13] was used to compare our 
discovered signatures with the published mutational 
signatures from pmsignature and from the COSMIC 
mutational signature website [2, 3]. iMutSig uses cosine 
similarity to compute the similarity of any two muta-
tional signatures. When comparing our five-base sig-
nature to the three-base signature in COSMIC, we sum 
the probabilities of the signature vector from the five-
base model over the features unmeasured in the three-
base model. Due to the independence assumption of 
our model, this is equivalent to a comparison using just 
the features shared in common by the two models.
Finally, we applied a hierarchical latent Dirichlet 
allocation model (HiLDA) [14] to test the equivalence 
of mutational signature exposures between trunk and 
branch mutations. We used the posterior distributions 
of the mean differences to test for differential exposures 
for any single signature (signature-level tests). The anal-
ysis was performed in R using the HiLDA package.
Results
Mutational signature analysis was applied to 127,748 
mutations from 431 COAD-US samples and 860 muta-
tions from 6 normal colon ASCs. The highest numbers 
of somatic mutations are found in the MMR-deficient, 
MSI-H and Pol ǫ cancers (Additional file 1: Figure S1). 
We fit the probability mutation signature model for dif-
ferent numbers of mutational signatures (2 through 8) 
and using the criteria of low bootstrap error and low 
BIC, selected six mutational signatures as having the 
best fit (Additional file 1: Figure S2).
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Figure 1 shows the six inferred mutational signatures 
along with the estimates of signature mutational expo-
sures. The six signatures included the four signatures 
previously identified by Shiraishi et al. [3] (red, orange, 
yellow, purple). The red signature was described as 
being due to aging, whereas the orange and yellow 
signatures were described as being due to the deregu-
lated activity of the polymerase Pol ǫ , while purple 
was of unknown origin. Two additional mutational 
signatures (cyan and blue, Fig. 1) were inferred to occur 
most frequently in MSI-H tumors, the blue signature 
also appearing in tumors with deregulated activity of 
the polymerase Pol ǫ . Deregulated polymerase activ-
ity is defined using mutational data (see [10]). The 
cyan signature reported a C > A substitution occur-
ring with a 5 ′  C; the blue signature identified C > T 
and T > C substitutions occurring with a 5 ′  G (Fig. 1). 
Both of these signatures resemble signatures previously 
Fig. 1 Signatures and their estimated mutational exposures for normal ASCs and COAD-US tumors. Six mutational signatures estimated from 6 
Normals and 431 COAD-US tumors (72 MSI-H, 80 MSI-L, and 279 MSS). Estimated mutational signatures (left) and signature mutational exposures 
(right), ordered as follows: Normal, MSI-H, MSI-L and MSS. In the figures to the left, each mutation feature is represented by a rectangle with colored 
area proportional to the expected frequency of each nucleotide. The more unequal the 4 nucleotide frequencies, the taller the rectangle. The five 
columns represent positions − 2, − 1, 0, 1, 2, relative to the single-base substitution. The upper right rectangles represent the expected frequency 
of the two transcription strands (+/−). Each signature is named by the color of the box enclosing it. These are ordered from top to bottom: red, 
orange, yellow, cyan, blue, purple. To the right, each vertical bar represents a tumor, and the colors indicate the relative frequency of that mutational 
signature in the tumor. The order of colors from top to bottom match the order of colors on the left (red to purple)
Table 1 Cosine similarities of  de-novo signatures (6 signatures in  Fig.  1) with  the  COSMIC (May 2019) single-base 
substitution signatures, and with the pmSignatures from Shiraishi’s paper
De-novo COSMIC pmSignature
Signatures SBS1 SBS6 SBS10a SBS10b SBS15 SBS20 SBS40 1 7 8 11 15 27
Red 0.830 0.778 0.020 0.238 0.530 0.214 0.281 0.002 0.863 0.215 0.317 0.305 0.034
Orange 0.002 0.014 0.943 0.260 0.050 0.087 0.353 0.991 0.013 0.015 0.002 0.139 0.152
Yellow 0.261 0.207 0.006 0.914 0.102 0.025 0.069 0.001 0.289 0.971 0.052 0.084 0.001
Cyan 0.004 0.042 0.108 0.041 0.116 0.884 0.279 0.175 0.024 0.002 0.005 0.173 0.876
Blue 0.267 0.737 0.036 0.108 0.844 0.250 0.204 0.005 0.462 0.139 0.791 0.485 0.028
Purple 0.157 0.354 0.270 0.263 0.322 0.415 0.911 0.225 0.379 0.153 0.159 0.815 0.292
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reported by Shiraishi et  al. [3] in stomach cancer 
(pmsignatures 11 and 27 with cosine similarities of 0.79 
and 0.88, respectively, Table  1). The six normal ASC 
and MMR-proficient tumor mutation catalogs were 
composed primarily of the red and purple signatures. 
For more on these samples see Additional file 1.
We compared our new signatures to those found in the 
COSMIC v89 May 2019 database (Mutational Signatures 
v3) (Table 1). Our blue signature resembles COSMIC sig-
nature SBS15, associated with defective DNA mismatch 
repair (cosine similarity 0.844). The new cyan signature 
resembles SBS20, reported to be associated with com-
bined deficiencies in DNA mismatch repair and POLD1 
proofreading (cosine similarity 0.884).
To investigate whether the signatures we detected in 
the tumors varied by the time of occurrence, we refit-
ted the mutational signature model to the subset of 93 
tumors with mutations grouped separately as trunk or 
branch. We specified and estimated four signatures only, 
as none of the 93 tumors carried the Pol ǫ signatures. 
The results in Fig. 2 show little discernible difference in 
mutational signature burden between trunk and branch 
mutations. Indeed, the MSI tumors show no evidence of 
differential trunk/branch mutational burden (all signa-
ture-specific 95% credible intervals include zero) (Addi-
tional file  1: Table  S2). Interestingly, the MSS tumors 
show a 9.6% higher mutational exposure of the red signa-
ture ( C > T at CpG) in trunk compared to branch muta-
tions (95% credible interval: 0.047–0.114).
Finally, we sought to replicate our mutational signa-
tures in an independent set of cancers from China. We 
apply the same probabilistic mutation signature model to 
the Chinese COCA-CN data set and identify the same six 
mutational signatures (Additional file 1: Figures S3, S4), 
replicating those extracted from the COAD-US data set. 
Although we lack information on tumor subtype, when 
ordering the tumors by the total number of mutations, a 
correlate for the MSI-H subtype, the pattern of estimated 
burdens for each mutational signature mimics those from 
the analysis of COAD-US cancers (see Additional file 1: 
Methods for details).
Discussion
We conducted a mutational signature analysis of colon 
adenocarcinomas from TCGA. We identified six muta-
tional signatures using the probabilistic mutational sig-
nature model with five-base patterns, whereas an early 
publication only reported four [3]. The ASCs from nor-
mal colon and MMR-proficient tumors showed a muta-
tional signature for aging, whereas the MMR-deficient 
tumors showed multiple MMR-related signatures.
Fig. 2 Branch–Trunk Signatures and their mutational exposures in COAD-US tumors. Four mutational signatures estimated from 186 samples of 
branch and trunk mutations from 93 COAD-US tumors. Estimated mutational signatures (left) and signature mutational exposures (right), ordered as 
follows: MSI-H branch, nonMSI-H branch, MSI-H trunk, nonMSI-H trunk. For more details see legend to Fig. 1
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A recent paper by Liu et al. also reported six signatures 
but allowed only three-base patterns in a more highly 
parameterized model [6]. The signatures from the two 
approaches were slightly different. Our model pooled 
substitutions with similar neighboring bases into a single 
signature (e.g. GpC > GpT and GpT > GpC in Fig. 1, blue) 
when theirs did not. Conversely, theirs combined sub-
stitutions with different neighboring bases into a single 
signature (CpC > CpA and GpC > GpT in COSMIC sig-
nature SBS6) when ours did not. The signatures we found 
replicated in an independent set of Chinese COCA-CN 
samples.
After classifying our mutations into time of occurrence, 
trunk or branch, we found the signature for aging (red) 
was more frequent in trunk than branch mutations from 
MSS tumors but the same was not true for MSI tumors. 
This replicates the results from an earlier study of MSS 
colon cancers that also found a higher mutational expo-
sure of the aging signature in trunk compared to branch 
mutations [14]. The lack of any new mutational signature 
in branch mutations, despite the different micro-environ-
ments of cancer from normal colon, is interesting.
Limitations
• TCGA published high-quality mutations from their 
Multi-Center Mutation Calling in Multiple Cancers 
(MC3) project in March 2018 [15], after the data 
for this paper were downloaded. The MC3 project 
reported variants on 389 (90%) of our 431 cancers, 
identifying 104,557 (82%) of the mutations we used 
for those same tumors. They identified 240585 vari-
ants, 1.9 times the number in our study. The smaller 
number of mutations in our analysis likely affected 
the precision of our estimates, and potentially also 
our sensitivity to detect new signatures. This limita-
tion could be more problematic for the analysis of 
trunk versus branch mutations as we are likely to be 
differentially missing more branch than trunk muta-
tions.
• The somatic mutation data from the Chinese COCA-
CN samples did not include variant allele frequency 
so we were unable to filter this data set using the 
same strict rules. Nevertheless, we still found evi-
dence for the same six signatures in colon cancer, and 
the burdens of the new signatures in MSI-H tumors 
were over-represented in the tumors with high muta-
tion burden. Therefore, despite not having informa-
tion on microsatellite instability of the cancer, we can 
roughly infer which tumors they are based on their 
mutational signatures and total mutation burden. 
This remains to be validated.
• Our new analysis discovered a signature with a 
preponderance of C > A substitutions, a common 
substitution for smoking, occurring at CpC sites. 
This signature appears in MSI-H tumors more fre-
quently than MSS tumors. At the same time, epi-
demiologic research has found that a history of 
smoking is more frequent in patients with MSI-H 
compared to MSS tumors [16, 17]. Unfortunately, 
we do not have information on smoking history for 
COAD-US patients to investigate this.
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